By targeting the Wnt signaling pathway, LGK974 offers an innovative approach to combat the excessive bone growth seen in sclerosteosis.

In vitro findings reveal Telomir-1’s dual action: targeting DNA methylation switches and cutting into the Wnt “fuel line” that drives cancer growth. MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025 ...

Researchers have explored the key benefits of employing aptamers in targeted therapies for orthopedic diseases. The flowchart ...

For decades, the biology of the intestinal stem cells was considered analogous to that of well-studied hematopoietic stem ...

Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to stenoparib, its investigational treatment for ...

Lower levels of natural lithium may increase amyloid plaques in brain regions vulnerable to Alzheimer’s — while a novel ...

A research team at Korea University's School of Medicine has identified the genetic cause of slow and non-hardening tooth ...